Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938228 | 0.88 | KMT2A (0.62) | ALDH1A1HPGDPOLBCYP2C19MAPK1 | |
| SCHEMBL29651063 | 0.88 | KMT2A (0.62) | ALDH1A1HPGDPOLBCYP2C19MAPK1 | |
| SCHEMBL10431594 | 0.88 | ALDH1A1 (0.59) | CETPALDH1A1HPGDPOLBCYP2C19 | |
| SCHEMBL14728026 | 0.87 | CETP (0.64) | CETPALDH1A1HPGDPOLBCYP2C19 | |
| SCHEMBL19924414 | 0.86 | CETP (0.58) | CETPALDH1A1HPGDPOLBCYP2C19 | |
| SCHEMBL1534076 | 0.84 | ALDH1A1 (0.55) | CETPALDH1A1HPGDPOLBCYP2C19 | |
| SCHEMBL9721425 | 0.84 | ALDH1A1 (0.55) | CETPALDH1A1HPGDPOLBCYP2C19 | |
| SCHEMBL6689158 | 0.82 | ALDH1A1 (0.74) | ALDH1A1HPGDPOLBCYP2C19MAPK1 | |
| SCHEMBL7223894 | 0.81 | CETP (0.53) | CETPALDH1A1HPGDPOLBCYP2C19 | |
| SCHEMBL28024836 | 0.81 | CETP (0.53) | CETPALDH1A1HPGDPOLBCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989263-B1 | Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-01-24 | — | — | US | claimed |
| US-20030198648-A1 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | ACHILION PHARMACEUTICALS | 2003-10-23 | — | — | US | claimed |
| WO-2003060098-A2 | METHODS FOR IDENTIFYING COMPOUNDS WHICH INHIBIT BINDING OF NUCLEOCAPSID 7 PROTEIN TO HIV-1 RNA | ACHILLION PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| EP-0782632-B1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | US GOV HEALTH & HUMAN SERV (US) | 2003-04-16 | — | — | EP | claimed |
| US-6001555-A | DISSOCIATING A ZINC FINGER BY CONTACTING THE PROTEIN WITH A DISULFIDE, A MALEIMIDE, AN ALPHA-HALOGENATED KETONE, A HYDRAZIDE, A NITRIC OXIDE OR DERIVATIVES, CUPRIC IONS, FERRIC IONS OR THEIR COMPLEXES; SYNERGISTIC EFFECTS WITH VIRICIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-14 | — | — | US | claimed |
| EP-0782632-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services (US) | 1997-07-09 | — | — | EP | claimed |
| WO-1996009406-A9 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | — | 1996-05-23 | — | — | WO | claimed |
| WO-1996009406-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-03-28 | — | — | WO | claimed |
| US-5194539-A | Of ethylenically unsaturated monomers where the aqueous dispersion is free from odor causing xanthogen disulfide | RHONE-POULENC CHIMIE (FR) | 1993-03-16 | — | — | US | claimed |
| US-20210338626-A1 | METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-11-04 | — | — | US | disclosed |
| US-20160160178-A1 | IMMUNOTHERAPY USING STEM CELLS | WHITE OAK IND INC (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150125489-A1 | METHOD FOR THE PREPARATION OF DENDRITIC CELL VACCINES | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2015-05-07 | — | — | US | disclosed |
| US-9000045-B2 | CETP activity inhibitors | JAPAN TOBACCO INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-9000045-B2 | CETP activity inhibitors | JAPAN TOBACCO INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| WO-1997044064-A2 | OLIGONUCLEOTIDES WHICH SPECIFICALLY BIND RETROVIRAL NUCLEOCAPSID PROTEINS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-27 | — | — | WO | disclosed |
| EP-0782632-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services (US) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996009406-A9 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | — | 1996-05-23 | — | — | WO | disclosed |
| WO-1996009406-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-03-28 | — | — | WO | disclosed |
| EP-0566080-A2 | Silver halide photographic emulsions sensitized in the presence of organic dichalcogenides | EASTMAN KODAK COMPANY (US) | 1993-10-20 | — | — | EP | disclosed |
| US-5194539-A | Of ethylenically unsaturated monomers where the aqueous dispersion is free from odor causing xanthogen disulfide | RHONE-POULENC CHIMIE (FR) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338626-A1 | METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION | ACE, ACE2, REN | CETP 64/4885ALDH1A1 4423/4885HPGD 2934/4885 |
| US-20160160178-A1 | IMMUNOTHERAPY USING STEM CELLS | CD14, ICOS, BMP4 | CETP 2173/4885ALDH1A1 1648/4885HPGD 4043/4885 |
| US-20150125489-A1 | METHOD FOR THE PREPARATION OF DENDRITIC CELL VACCINES | CCR7, CD69, CD14 | CETP 374/4885ALDH1A1 3097/4885HPGD 1616/4885 |
| US-20030198648-A1 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | MRPS27, SNRPE, NSUN2 | CETP 1104/4885ALDH1A1 4104/4885HPGD 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.